Cutera’s fractional laser wins Health Canada approval

According to the company, Pearl fractional is the only fractional ablative laser based on the 2,790nm wavelength with proprietary YSGG technology. Pearl fractional received FDA clearance and CE Mark approval in 2008.

Due to its specific water absorption characteristics, 2,790nm is an optimal laser wavelength for providing the dual benefit of deep dermal ablation with a controlled zone of thermal coagulation to maximize results while minimizing post-operative downtime, the company said.

Kevin Connors, president and CEO of Cutera, said: “Pearl fractional shipments are commencing immediately into the Canadian market. This approval confirms that Pearl fractional meets all health, safety and environmental standards required by Canada’s Ministry of Health.

“Pearl fractional is designed to safely and effectively repair deep dermal imperfections in just one treatment with an average recovery of five days. A recent study revealed that 94% of patients were extremely happy with their treatment results and 95% of patients would recommend a Pearl fractional treatment.”